Increase of Urokinase-type Plasminogen Activator Gene Expression in Human Lung and Breast Carcinomas

Cancer Research

Volumn 47, Issue 15, 1987, Pages 4043-4046

  Belin, Dominique ^b   Vassalli, Jean Dominique ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CARCINOMA; GENE EXPRESSION; HISTOPATHOLOGY; LUNG CARCINOMA; PRIORITY JOURNAL;

ADENOCARCINOMA; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, SQUAMOUS CELL; ENZYME INDUCTION; HUMAN; LUNG NEOPLASMS; LYMPHATIC METASTASIS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NUCLEIC ACID HYBRIDIZATION; PLASMINOGEN ACTIVATORS; RNA; RNA, COMPLEMENTARY; RNA, MESSENGER; RNA, NEOPLASM; SUPPORT, NON-U.S. GOV'T; URINARY PLASMINOGEN ACTIVATOR;

EID: 0023236992     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Rilke, L. F., Carbone, A., Clemente, C., and Pilotti, S. Surgical pathology of resectable lung cancer. Prog. Cancer Res. Ther., 11: 129–142, 1979.
2. Henderson, I. C., and Canellos, G. P. Cancer of the breast: the past decade. Part 1. New Engl. J. Med., 302: 17-30, 1980.
3. Fidler, I. J., Gersten, D. M., and Hart, I. R. The biology of cancer invasion and metastasis. Adv. Cancer Res., 28: 149-160, 1978.
4. Poste, G., and Fidler, I. J. The pathogenesis of cancer metastases. Nature (Lond.), 283: 139–146, 1980.
5. Liotta, L. A. Tumor invasion and metastases. Role of the extracellular matrix: Rhoads Memorial Award Lecture. Cancer Res., 46: 1–7, 1986.
6. Liotta, L. A., Truggvason, K., Garbisa, S., Hart, I., Foltz, C. M., and Shafie, S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature (Lond.), 284: 67-68, 1980.
7. Wang, B. S., McLaughling, G. A., and Richie, J. P. Correlation of the production of plasminogen activator with tumor metastasis in B16 melanoma cell lines. Cancer Res., 40: 228-232, 1980.
8. Carlsen, S. A., Ramshaw, I. A., and Warrington, R. C. Involvement of plasminogen activator production with tumor metastasis in a rat model. Cancer Res., 44: 3012-3016, 1984.
9. Reich, E. Activation of plasminogen: a widespread mechanism for generating localized extracellular proteolysis. In: R. W. Rudden (ed.), Biological Markers of Neoplasia: Basic and Applied Aspects, pp. 490–500. Amsterdam, Elsevier/North-Holland Biomedical Press, 1978.
10. Markus, G. The role of haemostasis and fibrinolysis in the metastatic spread of cancer. Semin. Thromb. Hemostasis, 10: 61-70, 1984.
11. Dano, K., Andreasen, P. A., Grondhal-Hansen, J., Kristensen, P., Nielsen, L. S., and Skriver, L. Plasminogen activators, tissue degradation and cancer. Adv. Cancer Res., 44: 139–266, 1985.
12. Unkeless, J. C., Tobia, A., Ossowski, L., Quigley, J. P., Rifkin, D. B., and Reich, E. An enzymatic function associated with transformation of fibroblasts by oncogenic viruses. I. Chick embryo fibroblast cultures transformed by avian RNA tumor viruses. J. Exp. Med., 137: 85-111, 1973.
13. Wigler, M., and Weinstein, I. B. Tumor promoter induces plasminogen activator. Nature (Lond.), 259: 232-233, 1976.
14. Skriver, L., Larsson, L. I., Kielberg, V., Nielsen, L. S., Andreasen, P. A., Kristensen, P., and Dano, K. Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. J. Cell Biol., 99: 753–758, 1984.
15. Ossowski, L., and Reich, E. Antibodies to plasminogen activator inhibit tumor metastasis. Cell, 35: 611-619, 1983.
16. Nagy, B., Ban, J., and Brdar, B. Fibrinolysis associated with human neoplasia. Production of plasminogen activator by human tumors. Int. J. Cancer, 19: 614–620, 1977.
17. Markus, G., Takita, H., Camiolo, S., Corasanti, J., Evers, J., and Hobika, G. H. Content and characterization of plasminogen activators in human lung tumors and normal lung tissue. Cancer Res., 40: 841-848, 1980.
18. Evers, J., Patel, J., Madeja, J. M., Schneider, S. L., Hobika, G. H., Camiolo, S. M., and Malkus, G. Plasminogen activator activity and composition in human breast cancer. Cancer Res., 42: 219–226, 1982.
19. Colombi, M., Barlati, S., Magdelenat, H., and Fiszer-Szafarz, B. Relationship between multiple forms of plasminogen activator in human breast tumors and plasma and the presence of metastases in lymphnodes. Cancer Res., 44: 2971–2975, 1984.
20. O'Grady, P. O., Lijnen, H. R., and Duffy, M. J. Multiple forms of plasminogen activator in human breast tumors. Cancer Res., 45: 6216-6218, 1985.
21. Malone, J. M., Gervin, A. S., Moore, W. S., and Keown, K. Tumor interaction with the fibrinolytic system. J. Surg. Res., 26: 581-589, 1979.
22. Saksela, O. Plasminogen activation and regulation of pericellular proteolysis. Biochim. Biophys. Acta, 823: 35-65, 1985.
23. Sprengers, E. D., and Kluft, C. Plasminogen activator inhibitors. Blood, 69: 381–387, 1987.
24. Kreyberg, L. Histologic typing of lung tumors. In: L. Kreyberg (ed.). International Histologic Classification of Tumors, No 1. Geneva: WHO, 19–26, 1967.
25. EORTC Breast Cancer Cooperative Group. Standards for the assessment of oestrogen receptors in human breast cancer. Eur. J. Cancer, 9: 379–381, 1973.
26. Busso, N., Belin, D., Failly-Crepin, C., and Vassalli, J. D. Plasminogen activators and their inhibitors in a human mammary cell line (HBL-100): modulation by glucocorticoids. J. Biol. Chem., 261: 9309-9315, 1986.
27. Verde, P., Stoppelli, M. P., Galleffi, M., Di Nocera, P., and Blasi, F. Identification and primary sequence of an unspliced human urokinase poly (A) + RNA. Proc. Natl. Acad. Sci. USA, 81: 4727-4731, 1984.
28. Fisher, R., Waller, E. K., Grossi, G., Thompson, D., Tizard, R., and Schleuning, W. Isolation and characterization of the human tissue-type plasminogen activator structural gene including its 5' flanking region. J. Biol. Chem., 260: 11223–11230, 1985.
29. Melton, D. A., Krief, P. A., Rebagliati, M. R., Maniatis, T., Zinn, K., and Green, M. R. Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter. Nucleic Acids Res., 12: 7035-7056, 1984.
30. Maniatis, T., Fritsch, E. F., and Sambrook, J. Molecular cloning, a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1982.
31. White, B. A., and Bancroft, F. C. Cytoplasmic dot hybridization. Simple analysis of relative mRNA levels in multiple small cell or tissue samples. J. Biol. Chem., 15: 8569-8572, 1982.
32. Ossowski, L., and Belin, D. Effect of dimethyl sulfoxide on human carcinoma cells: inhibition of plasminogen activator synthesis, change in cell morphology and alteration of response to cholera toxin. Mol. Cell. Biol., 12: 3552–3559, 1985.
33. Wun, T. C., Ossowski, L., and Reich, E. A proenzyme form of human urokinase. J. Biol. Chem., 12: 7262-7274, 1982.
34. Vassalli, J. D., Dayer, J. M., Wohlwend, A. L., and Belin, D. Concomitant secretion of prourokinase and of a plasminogen activator-specific inhibitor by cultured monocytes-macrophages. J. Exp. Med., 159: 1653-1668, 1984.
35. Tissot, J. D., Hauert, J., and Bachmann, F. Characterization of plasminogen activators from normal breast and colon and from breast and colon carcinomas. Int. J. Cancer, 34: 295–302, 1984.
36. Vassalli, J. D., Baccino, D., and Belin, D. A cellular binding site for the Mr 55, 000 form of the human plasminogen activator urokinase. J. Cell Biol., 100: 86-92, 1985.
37. Ossowski, L., Biegel, D., and Reich, E. Mammary plasminogen activator correlation with involution, hormonal modulation and comparison between normal and neoplastic tissue. Cell, 16: 929-940, 1979.
38. Busso, N., Belin, D., Failly-Crepin, C., and Vassalli, J-D. Glucocorticoid modulation of plasminogen activators and of one of their inhibitors in the human mammary carcinoma cell line MDA-MB-231. Cancer Res., 47: 364-370, 1987.
39. Sainsbury, J. R. C., Farndon, J. R., Sherbet, G. V., and Harris, A. L. Epidermal growth factor receptors and oestrogen receptors in human breast cancer. Lancet, 1: 364-366, 1985.
40. Stopelli, M. P., Verde, P., Grimmaldi, G., Locatelli, E. K., et al. Increase in urokinase plasminogen activator mRNA synthesis in human carcinomas cells is a primary effect of the potent tumor promoter, phorbol myristate acetate. J. Cell. Biol., 102: 1235-1241, 1986.
41. Mira-Lopez, R., Joseph-Silverstein, J., Rifkin, D. B., and Ossowski, L. Identification of a pituitary factor responsible for enhancement of plasminogen activator activity in breast tumor cells. Proc. Natl. Acad. Sci. USA, 83: 7780–7784, 1986.